Envisagenics

Overview

Envisagenics is an AI-driven biotechnology company headquartered in Long Island City, New York[1]. Founded in 2014 as a spin-out from Cold Spring Harbor Laboratory by co-founder and CEO Maria Luisa Pineda, PhD[4], the company describes itself as a woman- and minority-led organization[4]. Envisagenics discovers and develops therapeutic treatments by targeting RNA splicing for oncology and neurodegeneration using its AI platform SpliceCore[2]. SpliceCore is a cloud-based drug discovery platform that integrates machine learning with high performance computing and draws on a proprietary database of more than 14 million RNA splicing events[5]. The company has established research collaborations with Biogen, the Lung Cancer Initiative at Johnson & Johnson, and Bristol Myers Squibb[7]. In June 2024, Envisagenics announced a Series B funding round with participation from Third Kind Venture Capital, Empire State Development, Red Cell Partners, and Bristol Myers Squibb[6].

Headquartered at 30-02 48th Ave, Suites 140 and 150, Long Island City, New York NY 11101 [2]

Envisagenics was founded in 2014 as a spin-out from Cold Spring Harbor Laboratory by co-founder and CEO Maria Luisa Pineda, PhD, and describes itself as a woman- and minority-led organization. [4]

SpliceCore is a cloud-based AI drug discovery platform that integrates machine learning with high performance computing and draws on a proprietary database of more than 14 million RNA splicing events, giving a 400-fold increase in transcriptomic search space compared to conventional target identification tools. [5]

Envisagenics is located at 30-02 48th Ave, Suites 140 and 150, Long Island City, New York NY 11101. [9]

Business address: 30-02 48th Ave, New York, New York, 11101. [11]

Funding history

Envisagenics announced a Series B round on 4 June 2024 with participation from existing investors Third Kind Venture Capital, Empire State Development and Red Cell Partners, plus new strategic investor Bristol Myers Squibb, following a Series A announced in September 2021. [6]

Partnerships

Envisagenics has established research collaborations with Biogen, the Lung Cancer Initiative at Johnson & Johnson, and Bristol Myers Squibb, which entered an oncology research collaboration in 2022. [7]

Growth & traction

CEO Maria Luisa Pineda said in June 2024 that Envisagenics is a profitable company with a strong AI/ML platform, a brilliant team and world-class collaborations, focused on product and asset development. [8]